Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Removal of Basiliximab by plasmapheresis
Autore:
Okechukwu, CN; Meier-Kriesche, HU; Armstrong, D; Campbell, D; Gerbeau, C; Kaplan, B;
Indirizzi:
Univ Michigan, Div Nephrol, Ann Arbor, MI 48109 USA Univ Michigan Ann Arbor MI USA 48109 Div Nephrol, Ann Arbor, MI 48109 USA Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA Univ Michigan Ann ArborMI USA 48109 , Dept Surg, Ann Arbor, MI 48109 USA
Titolo Testata:
AMERICAN JOURNAL OF KIDNEY DISEASES
fascicolo: 1, volume: 37, anno: 2001,
pagine: NIL_111 - NIL_113
SICI:
0272-6386(200101)37:1<NIL_111:ROBBP>2.0.ZU;2-N
Fonte:
ISI
Lingua:
ENG
Soggetto:
HEMOLYTIC-UREMIC SYNDROME; ACUTE CELLULAR REJECTION; MONOCLONAL-ANTIBODY; RENAL-TRANSPLANTATION; RECIPIENTS; ALLOGRAFTS;
Keywords:
Basiliximab; simulect; plasmapheresis; renal transplantation;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
10
Recensione:
Indirizzi per estratti:
Indirizzo: Kaplan, B Univ Michigan Hlth Syst, Taubman Ctr 3914, Box 0364,1500 E Med Ctr Dr, AnnArbor, MI 48109 USA Univ Michigan Hlth Syst Box 0364,1500 E Med Ctr Dr Ann Arbor MI USA 48109
Citazione:
C.N. Okechukwu et al., "Removal of Basiliximab by plasmapheresis", AM J KIDNEY, 37(1), 2001, pp. NIL_111-NIL_113

Abstract

Basiliximab is a chimeric monoclonal antibody directed against the alpha chain of interleukin-2 (IL-2) receptors, Given its expected volume of distribution (plasma volume), therapeutic plasmapheresis may be expected to lowerserum Basiliximab levels. A 20 mg dose of Basiliximab was given before plasmapheresis, Blood and pheresis fluid samples were obtained to monitor Basiliximab levels. A total of three blood samples were drawn: the first was obtained 4 hours before, the second sample immediately before commencement, and the third 2 hours after cessation of plasmapheresis. A fourth sample wasobtained from the removed plasma. There was an appreciable reduction in Basiliximab concentration levels after plasmapheresis, From the change in serum concentration after plasmapheresis, approximately 64.6% of circulating Basiliximab was removed. Plasmapheresis removes substantial amounts of Basiliximab. Therefore, supplemental Basiliximab should be given after plasmapheresis to maintain the desired duration of IL-2R saturation. (C) 2001 by theNational Kidney Foundation, Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/09/20 alle ore 15:15:31